Pfizer (PFE) EBITDA (2009 - 2026)

Pfizer (PFE) has 18 years of EBITDA data on file, last reported at -$6.7 billion in Q1 2026.

• EBITDA for Q1 2026 came in at -$6.7 billion, down 0.98% year-over-year; the trailing twelve-month figure through Mar 2026 was -$17.7 billion (down 83.68% YoY), and the FY2025 annual result was $20.7 billion, up 156.03% from the prior year.
• EBITDA fell to -$6.7 billion in Q1 2026 per PFE's latest filing, from $4.2 billion in the prior quarter.
• Over five years, EBITDA peaked at $13.0 billion in Q3 2022 and troughed at -$13.8 billion in Q4 2023.
• A 5-year average of -$2.2 billion and a median of -$6.6 billion in 2025 frame the typical range for EBITDA.
• The sharpest annual moves came in 2024 and 2025: EBITDA soared 177.08% in 2024, then plunged 397.16% in 2025.
• A 5-year view of EBITDA shows it stood at $10.3 billion in 2022, then tumbled by 227.15% to -$13.1 billion in 2023, then gained by 16.28% to -$11.0 billion in 2024, then jumped by 137.82% to $4.2 billion in 2025, then sank by 261.62% to -$6.7 billion in 2026.
• Business Quant data shows PFE's EBITDA at -$6.7 billion in Q1 2026, $4.2 billion in Q4 2025, and -$7.8 billion in Q3 2025.